Biogen (MIL:1BIIB) Beneish M-Score : -2.56 (As of Dec. 11, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Biogen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.56 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Biogen's Beneish M-Score or its related term are showing as below:

MIL:1BIIB' s Beneish M-Score Range Over the Past 10 Years
Min: -3.05 Med: -2.62 Max: -2.12
Current: -2.56

During the past 13 years, the highest Beneish M-Score of Biogen was -2.12. The lowest was -3.05. And the median was -2.62.

Biogen Beneish M-Score Historical Data

The historical data trend for Biogen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Beneish M-Score Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

-2.67

-2.84

-2.91

-2.22

-2.31

Biogen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beneish M-Score	Get a 7-Day Free Trial															-2.18	-2.31	-2.34	-2.37	-2.56

Competitive Comparison of Biogen's Beneish M-Score

For the Drug Manufacturers - General subindustry, Biogen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biogen's Beneish M-Score falls into.

Biogen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biogen for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.9175

0.528 * 0.9937

0.404 * 1.1151

0.892 * 0.943

0.115 * 0.7389

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.9419

4.679 * -0.013397

0.327 * 0.8404

-2.59

This Year (Sep24) TTM:

Last Year (Sep23) TTM:

Total Receivables was €1,791 Mil.
Revenue was 2221.686 + 2289.892 + 2107.26 + 2188.237 = €8,807 Mil.
Gross Profit was 1646.217 + 1782.658 + 1608.436 + 1621.256 = €6,659 Mil.
Total Current Assets was €6,154 Mil.
Total Assets was €25,510 Mil.
Property, Plant and Equipment(Net PPE) was €3,236 Mil.
Depreciation, Depletion and Amortization(DDA) was €576 Mil.
Selling, General, & Admin. Expense(SGA) was €2,138 Mil.
Total Current Liabilities was €4,888 Mil.
Long-Term Debt & Capital Lease Obligation was €4,417 Mil.
Net Income was 350.039 + 542.164 + 361.928 + 228.975 = €1,483 Mil.
Non Operating Income was 2.523 + 35.302 + -49.128 + -108.573 = €-120 Mil.
Cash Flow from Operations was 842.976 + 581.368 + 508.944 + 11.462 = €1,945 Mil.

Total Receivables was €2,070 Mil.
Revenue was 2370.891 + 2266.888 + 2300.442 + 2401.536 = €9,340 Mil.
Gross Profit was 1752.846 + 1719.826 + 1681.387 + 1862.606 = €7,017 Mil.
Total Current Assets was €7,921 Mil.
Total Assets was €26,417 Mil.
Property, Plant and Equipment(Net PPE) was €3,525 Mil.
Depreciation, Depletion and Amortization(DDA) was €443 Mil.
Selling, General, & Admin. Expense(SGA) was €2,407 Mil.
Total Current Liabilities was €4,706 Mil.
Long-Term Debt & Capital Lease Obligation was €6,761 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1791.278 / 8807.075)	/	(2070.489 / 9339.757)
	=	0.203391	/	0.221686
	=	0.9175

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(7016.665 / 9339.757)	/	(6658.567 / 8807.075)
	=	0.751268	/	0.756047
	=	0.9937

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (6154.281 + 3235.761) / 25510.193)	/	(1 - (7921.492 + 3525.463) / 26417.028)
	=	0.63191	/	0.566683
	=	1.1151

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	8807.075	/	9339.757
	=	0.943

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(443.464 / (443.464 + 3525.463))	/	(576.493 / (576.493 + 3235.761))
	=	0.111734	/	0.151221
	=	0.7389

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(2137.602 / 8807.075)	/	(2406.78 / 9339.757)
	=	0.242714	/	0.257692
	=	0.9419

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((4417.423 + 4887.925) / 25510.193)	/	((6760.642 + 4705.895) / 26417.028)
	=	0.36477	/	0.434059
	=	0.8404

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(1483.106 - -119.876	-	1944.75)	/	25510.193
	=	-0.013397

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biogen has a M-score of -2.59 suggests that the company is unlikely to be a manipulator.

Biogen Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Biogen's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MIL:1BIIB) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines